A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Clinical trial NCT07629960 · RECRUITING

Trial details

NCT number: NCT07629960
Sponsor: Blueprint Medicines Corporation
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Non-Small Cell Lung Cancer Colorectal Neoplasms Pancreatic Ductal Adenocarcinoma

Start date: 2026-06-04
Primary completion: 2029-09-01
Enrollment: 265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.